Asparaginase for injection

Some tumor cells (such as lymphoblastic leukemia cells) lack asparagine synthetase, so they cannot synthesize asparagine necessary for growth by themselves and must rely on the host for supply. This product can catalyze the decomposition of asparagine into aspartic acid and ammonia, so it can make these tumor cells lack asparagine, thereby interfering with their protein synthesis and inhibiting cell growth. This product may be specific to G1 phase cells. Initially, it was believed that the presence or absence of asparagine synthetase was a unique biochemical difference between normal cells and tumor cells. However, it has been found that many normal cells are also sensitive to asparaginase. In addition, there are cell lines containing asparagine synthetase in human leukemia cells, which can quickly develop drug resistance. Therefore, when this product is used for tumor treatment, it should not be used alone or as a maintenance treatment, but should be used in combination with other anticancer drugs.

This product is a white freeze-dried block

The remission rate of acute lymphocytic leukemia can reach more than 50%. It also has a certain effect on acute myeloid leukemia, acute monocytic leukemia and malignant lymphoma. It is often used in combination with vinblastine, prednisone, cytarabine, mercaptopurine, methotrexate, etc. to improve the efficacy and reduce the occurrence of drug resistance. Vincristine should be administered before asparaginase. If this product is given first, it will damage the liver's clearance of vincristine. The immunosuppressive effect of this product can also be used clinically to treat dermatomyositis.

Generally, it is injected or dripped intravenously, 40-200U/kg each time, once a day or every other day, and gradually increased to 1000U/kg according to the tolerance. Dilute the intravenous injection with 20-40ml normal saline, and dilute the intravenous drip with 500ml of 5% glucose solution, 10-20 times as a course. Intramuscular injection: The dose is the same as the intravenous injection, dissolved with 5-10ml normal saline. When used in combination with prednisone and vincristine to treat acute lymphoblastic leukemia in children, 1000U/kg can be dripped intravenously every day, after the use of prednisone and vincristine, that is, starting from the 22nd day after treatment, for 10 consecutive days. If it is given before or at the same time as the above drugs, it will enhance adverse reactions. Intramuscular injection: When used in combination with prednisone and vincristine, 6000U/㎡ each time is given once every 3 days starting from the 4th day, for a total of 9 doses.

Toxicity is the main factor limiting the effect of this product, which mainly comes from the rabbit allergic reaction caused by foreign proteins and the result of reduced protein synthesis. Allergic reactions can range from urticaria to anaphylactic shock, with an incidence of 10% to 15%. It can occur in the initial course of treatment, but is more common when the drug is given again. If the dosing interval is 7 days or longer, the incidence of allergies increases. Before use (including changing batch numbers), a skin test of 10 to 50 U/0.1 ml should be performed and observed for 3 hours. Only those with negative results can be used, but a negative skin test cannot completely confirm that allergic reactions will not occur. Be alert to the possibility of anaphylactic shock, and appropriate support measures should be prepared. Intravenous epinephrine can generally terminate allergic reactions.

Pregnant and lactating women.

10,000 units

Wuzhi Weierkang Biochemical Pharmaceutical Co., Ltd.

• Founded in:

  1991-05-03

• Address:

  No. 331, Xingye Road, Wuzhi County Industrial Cluster Area

• Tax NO.:

  913701121631595699

• Registered Funds:

  5 million yuan

• Email:

  Log in to view